摄碘阳性的分化型甲状腺癌淋巴结转移灶131I疗效分析

梅晓然, 冯方, 王辉, 韦智晓

  1. 1.广西医科大学第一附属医院核医学科,广西 南宁 530021
    2.上海交通大学医学院附属新华医院核医学科,上海 200092
  • 收稿日期:2022-05-31 修回日期:2022-08-17 出版日期:2022-11-30 发布日期:2022-12-14
  • 通信作者: 韦智晓
  • 作者简介:梅晓然(ORCID: 0000-0003-1289-7778),硕士。
  • 基金资助:
    国家自然科学基金面上项目(81974269)

摘要/Abstract

摘要:

背景与目的:淋巴结转移(lymph node metastasis,LNM)是分化型甲状腺癌(differentiated thyroid carcinoma,DTC)最常见的转移,而131I对LNM的疗效存在争议,本研究旨在明确131I对摄碘良好的LNM的疗效及影响因素。方法:纳入2015年1月—2019年6月在上海交通大学医学院附属新华医院接受131I治疗的90例DTC患者,共计161个摄碘阳性的转移淋巴结。分析患者的临床及影像学资料,应用SPSS 24.0软件进行统计分析。计量资料按照正态分布,进行独立样本t检验比较,计数资料的比较采用χ2检验,用logistic回归进行多因素分析,建立多个定量指标与结局为131I治疗无效的关系间的受试者工作特征(receiver operating characteristic,ROC)曲线,并得到最佳诊断阈值。结果:161个摄碘阳性的转移淋巴结中,有效组为71个(44.10%),无效组为90个(55.90%)。单因素分析提示,两组患者在年龄、性别、病理学类型、原发病灶数量、原发病灶位置、有无远处转移及血清甲状腺球蛋白(thyroglobulin,Tg)水平等方面差异均有统计学意义(P <0.05)。多变量logistic回归分析显示,病理学类型(OR = 11.827,95% CI:1.128 ~ 123.978,P = 0.039)、有无远处转移(OR = 0.220,95% CI:0.093 ~ 0.522,P = 0.001)和原发病灶数量(OR = 0.421,95% CI:0.212 ~ 0.837,P = 0.014)与治疗后的转归密切相关。结论:原发病灶多灶、病理学类型为甲状腺乳头状癌(papillary thyroid carcinoma,PTC)、远处转移、血清Tg高于43.51 ng/mL及转移淋巴结的最大径大于16.8 mm是摄碘阳性淋巴结131I治疗无效的危险因素,建议对此类患者加大治疗剂量或尽早选择手术切除。

关键词: 分化型甲状腺癌, 摄碘阳性, 淋巴结转移, 疗效分析

Abstract:

Background and purpose: Lymph node metastasis (LNM) is the most common metastasis of differentiated thyroid cancer (DTC), and the efficacy of 131I on LNM is controversial. The aim of this study was to clarify the efficacy of 131I on LNM with good iodine uptake and the influencing factors. Methods: In this study, 161 iodine positive metastasis lymph nodes from 90 DTC patients treated by 131I from January 2015 to June 2019 in Xinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine were included, and the clinical and imaging data of the patients were analyzed. SPSS 24.0 software was used to make statistical analysis. The measurement data were distributed according to the normal distribution, then the independent sample t-test was compared. The comparison of the counting data was conducted by χ2 test, and the multivariate analysis was carried out by logistic regression analysis. The receiver operating characteristic (ROC) curve between multiple quantitative indexes and the failure of 131I treatment were established, and the optimal diagnostic threshold was obtained. Results: Among 161 iodine positive metastasis lymph nodes, 71 (44.10%) were effective, and 90 (55.90%) were ineffective. Univariate analysis showed that there were significant differences in age, gender, pathological type, number of primary lesions, location of primary lesions, distant metastasis and serum thyroglobulin (Tg) level between the two groups (P<0.05). Multivariate logistic regression analysis showed that the pathological types (OR = 11.827, 95% CI: 1.128-123.978, P = 0.039), distant metastasis (OR = 0.220, 95% CI: 0.093-0.522, P = 0.001) and number of primary lesions (OR = 0.421, 95% CI: 0.212-0.837, P = 0.014) were closely related to the outcome of the treatment. Conclusion: Multiple primary foci, papillary thyroid carcinoma (PTC), distant metastasis, serum Tg higher than 43.51 ng/mL and the maximum diameter of metastatic lymph nodes greater than 16.8mm are the risk factors of ineffective 131I treatment. Increasing the treatment dose or choosing surgical resection as soon as possible is recommended for those patients.

Key words: Differentiated thyroid cancer, Iodine positive, Lymph node metastasis, Efficacy analysis

中图分类号: 

相关文章

[1] 郑秀丽, 姚志原, 吴明利, 尔丽绵, 李胜棉. 直肠神经内分泌肿瘤淋巴结转移的危险因素分析及内镜切除方式比较[J]. 中国癌症杂志, 2022, 32(9): 800-806.
[2] 邓姝婷, 冯源, 钱凯, 郭凯, 王卓颖. 基因突变特征与儿童及青少年分化型甲状腺癌远处转移相关性的meta分析[J]. 中国癌症杂志, 2022, 32(5): 388-396.
[3] 齐萌芳, 田甜, 黄蕤. 不同年龄儿童及青少年分化型甲状腺癌患者的临床病理学特征与131I治疗分析[J]. 中国癌症杂志, 2022, 32(5): 404-409.
[4] 郭文婷, 慕转转, 李征, 张迎强, 靳晓娜, 林岩松. 可疑甲状腺球蛋白增高性分化型甲状腺癌患者经131I治疗后的临床转归[J]. 中国癌症杂志, 2022, 32(5): 410-416.
[5] 中国临床肿瘤学会核医学专家委员会, 中国临床肿瘤学会甲状腺癌专家委员会, 中国医疗保健国际交流促进会甲状腺疾病专业委员会, 中国人口文化促进会甲状腺疾病防治专业委员会. 儿童及青少年分化型甲状腺癌核医学诊治中国专家共识(2022年版)[J]. 中国癌症杂志, 2022, 32(5): 451-468.
[6] 蒋朝阳, 王 娟, 张 伶, 高 辉, 张 涛, 李智慧 . 709例鼻咽癌颈部各区淋巴结转移的相关性分析[J]. 中国癌症杂志, 2021, 31(7): 629-634.
[7] 董诗洁, 胡晓欣, 王 葳, 杨 孟, 岳 磊, 童 彤, 顾雅佳. 基于多序列MRI与多体系影像组学模型预测子宫颈癌淋巴结转移的研究[J]. 中国癌症杂志, 2021, 31(6): 460-467.
[8] 於 雷 , 代 智 , 王 征 , 张 勇 , 陈 青 . 淋巴结转移对肝内胆管细胞癌患者预后的影响及临床相关因素研究[J]. 中国癌症杂志, 2020, 30(9): 694-700.
[9] 李梦蕾, 张 敬, 淡一波, 杨 光, 姚叶锋, 童 彤 . 术前预测结直肠癌淋巴结转移的临床-影像组学列线图的建立和验证[J]. 中国癌症杂志, 2020, 30(1): 49-56.
[10] 马小开,黄建康,朱? 博 1,彭德峰,周? 锐,王圣应 . 228例甲状腺微小乳头状癌临床特征及颈部淋巴结转移危险因素分析[J]. 中国癌症杂志, 2019, 29(8): 590-594.
[11] 杨 珂,郑 容,林岩松. 儿童青少年甲状腺癌诊治指南解读及其进展——核医学部分[J]. 中国癌症杂志, 2019, 29(6): 401-411.
[12] 张立阳,刘春浩,曹 越,刘洪沨,高维生,李小毅. 125例复发/持续性分化型甲状腺癌再次手术及其预后影响因素分析[J]. 中国癌症杂志, 2019, 29(6): 412-417.
[13] 眭慧敏,刘杰蕊,王 瞳,朱朝晖,林岩松. 儿童及青少年分化型甲状腺癌远处转移的临床病理学危险因素分析[J]. 中国癌症杂志, 2019, 29(6): 423-428.
[14] 卢承慧,李 娇,刘新峰,王国强,王增华,王叙馥. 治疗前刺激性甲状腺球蛋白阴性合并淋巴结转移的分化型甲状腺癌131I治疗后的临床转归[J]. 中国癌症杂志, 2019, 29(6): 429-433.
[15] 张 娜,林岩松,梁 军. 甲状腺球蛋白抗体测定在分化型甲状腺癌131I治疗中的临床意义[J]. 中国癌症杂志, 2019, 29(6): 452-456.